Marjan Javanbakht1, Steven Shoptaw2, Amy Ragsdale3, Ron Brookmeyer4, Robert Bolan5, Pamina M Gorbach3. 1. UCLA Fielding School of Public Health, Department of Epidemiology, Los Angeles, CA, United States. Electronic address: javan@ucla.edu. 2. UCLA David Geffen School of Medicine, Department of Family Medicine, Los Angeles, CA, United States. 3. UCLA Fielding School of Public Health, Department of Epidemiology, Los Angeles, CA, United States. 4. UCLA Fielding School of Public Health, Department of Biostatistics, Los Angeles, CA, United States. 5. Los Angeles LGBT Center, Los Angeles, CA, United States.
Abstract
BACKGROUND: The objective of this study was to examine depressive symptoms overtime and quantify the variance in symptoms attributable to substance use among a cohort of HIV-positive and HIV-negative men. METHODS: Participants were enrolled in an NIH/NIDA funded cohort, with 534 men resulting in 1,888 visits between August 2014 and June 2018. Participants were between 18 and 45 years, and half were HIV-positive. At baseline and semi-annual visits, information was collected on depressive symptoms, sexual behaviors, and substance use. Changes overtime in symptom scores were evaluated using individual growth curve modeling. RESULTS: The average CES-D20 score was 19.5 (SD = 12.7). Depressive symptoms were highest among daily/weekly methamphetamine users (56% vs. 39% occasional users and 27% non-users; p value<.01). Factors independently associated with depressive symptoms included methamphetamine use (adjusted OR = 1.5; 95% CI 1.1-2.3) and transactional sex (adjusted OR = 1.8; 95% CI 1.4-2.5). Based on growth curve modeling, methamphetamine was the most influential predictor of depressive symptoms, accounting for 10% of individual variance (p value<.01). Declines in depressive symptoms were noted for heavy users of a number of drugs, except for methamphetamine. For instance, those reporting daily/weekly heroin had a 3.38 point decline in CESD20 scores overtime (p value = 0.01). However, heavy methamphetamine users had much higher CESD20 scores and their scores remained high overtime (p value for change = 0.91). CONCLUSIONS: The prevalence of depressive symptoms among this cohort of HIV-negative and HIV-positive MSM was high, especially among frequent methamphetamine users. These findings suggest that reducing methamphetamine use may have the potential to reduce depressive symptoms.
BACKGROUND: The objective of this study was to examine depressive symptoms overtime and quantify the variance in symptoms attributable to substance use among a cohort of HIV-positive and HIV-negative men. METHODS:Participants were enrolled in an NIH/NIDA funded cohort, with 534 men resulting in 1,888 visits between August 2014 and June 2018. Participants were between 18 and 45 years, and half were HIV-positive. At baseline and semi-annual visits, information was collected on depressive symptoms, sexual behaviors, and substance use. Changes overtime in symptom scores were evaluated using individual growth curve modeling. RESULTS: The average CES-D20 score was 19.5 (SD = 12.7). Depressive symptoms were highest among daily/weekly methamphetamine users (56% vs. 39% occasional users and 27% non-users; p value<.01). Factors independently associated with depressive symptoms included methamphetamine use (adjusted OR = 1.5; 95% CI 1.1-2.3) and transactional sex (adjusted OR = 1.8; 95% CI 1.4-2.5). Based on growth curve modeling, methamphetamine was the most influential predictor of depressive symptoms, accounting for 10% of individual variance (p value<.01). Declines in depressive symptoms were noted for heavy users of a number of drugs, except for methamphetamine. For instance, those reporting daily/weekly heroin had a 3.38 point decline in CESD20 scores overtime (p value = 0.01). However, heavy methamphetamine users had much higher CESD20 scores and their scores remained high overtime (p value for change = 0.91). CONCLUSIONS: The prevalence of depressive symptoms among this cohort of HIV-negative and HIV-positive MSM was high, especially among frequent methamphetamine users. These findings suggest that reducing methamphetamine use may have the potential to reduce depressive symptoms.
Authors: B F Grant; R B Goldstein; S P Chou; B Huang; F S Stinson; D A Dawson; T D Saha; S M Smith; A J Pulay; R P Pickering; W J Ruan; W M Compton Journal: Mol Psychiatry Date: 2008-04-22 Impact factor: 15.992
Authors: Bridget F Grant; Tulshi D Saha; W June Ruan; Risë B Goldstein; S Patricia Chou; Jeesun Jung; Haitao Zhang; Sharon M Smith; Roger P Pickering; Boji Huang; Deborah S Hasin Journal: JAMA Psychiatry Date: 2016-01 Impact factor: 21.596
Authors: Stephanie K Y Choi; Eleanor Boyle; John Cairney; Evan J Collins; Sandra Gardner; Jean Bacon; Sean B Rourke Journal: PLoS One Date: 2016-11-01 Impact factor: 3.240
Authors: Stephanie K Y Choi; Eleanor Boyle; Ann N Burchell; Sandra Gardner; Evan Collins; Paul Grootendorst; Sean B Rourke Journal: PLoS One Date: 2015-11-13 Impact factor: 3.240
Authors: Chukwuemeka N Okafor; Mark Brennan-Ing; Deanna Ware; Sabina Haberlen; James E Egan; Andre L Brown; Steven Meanley; Valentina Stosor; Steven Shoptaw; M Reuel Friedman; Michael Plankey Journal: Aging Ment Health Date: 2022-02-09 Impact factor: 3.514
Authors: David A Wiss; Marjan Javanbakht; Michael J Li; Michael Prelip; Robert Bolan; Steve Shoptaw; Pamina M Gorbach Journal: Public Health Nutr Date: 2021-06-09 Impact factor: 4.539
Authors: Ji-Young Lee; Tiffany R Glynn; Judith T Moskowitz; Dietmar Fuchs; Torsten B Neilands; Samantha E Dilworth; Daniel J Feaster; Allan Rodriguez; Adam W Carrico Journal: J Neurovirol Date: 2021-01-18 Impact factor: 3.739
Authors: Rayner Kay Jin Tan; Caitlin Alsandria O'Hara; Wee Ling Koh; Daniel Le; Avin Tan; Adrian Tyler; Calvin Tan; Chronos Kwok; Sumita Banerjee; Mee Lian Wong Journal: BMC Public Health Date: 2021-05-31 Impact factor: 3.295
Authors: Steven Meanley; Seul Ki Choi; Azure B Thompson; Jacquelyn L Meyers; Gypsyamber D'Souza; Adaora A Adimora; Matthew J Mimiaga; Mirjam-Colette Kempf; Deborah Konkle-Parker; Mardge H Cohen; Linda A Teplin; Lynn Murchison; Leah H Rubin; Anna A Rubtsova; Deborah Jones Weiss; Brad Aouizerat; Mackey R Friedman; Michael W Plankey; Tracey E Wilson Journal: Drug Alcohol Depend Date: 2021-12-25 Impact factor: 4.492